| MeSH term | MeSH ID | Detail |
|---|---|---|
| Keratosis, Actinic | D055623 | 3 associated lipids |
| Invasive Pulmonary Aspergillosis | D055744 | 1 associated lipids |
| Latent Tuberculosis | D055985 | 1 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Leukoencephalopathies | D056784 | 3 associated lipids |
| Central Serous Chorioretinopathy | D056833 | 1 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Candidiasis, Invasive | D058365 | 2 associated lipids |
| End Stage Liver Disease | D058625 | 1 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| Drug-Related Side Effects and Adverse Reactions | D064420 | 3 associated lipids |
| Scorpion Stings | D065008 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
| Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
| Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
| Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
| Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
| Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
| Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
| Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
| McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Takabayashi K et al. | Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. | 1989 | Clin. Immunol. Immunopathol. | pmid:2466594 |
| Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
| Siekierka JJ et al. | FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. | 1989 | J. Immunol. | pmid:2474605 |